Tempus AI announces results from ALERT trial, study met primary endpoint

Tempus AI (TEM) announced results from the ALERT trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic clinician notifications integrated into the electronic health record significantly improve the timely evaluation and treatment of patients with significant aortic stenosis and mitral regurgitation. The ALERT trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis, meaning patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group. By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care.

Claim 55% Off TipRanks